We have developed a novel class (2-amino-4-phenyl-4H-chromene-3-carboxylate) of inhibitors of tubulin assembly by modifying HA14-1, which is a Bcl-2 inhibitor discovered by our group. Three of these compounds, mHA1, mHA6, and mHA11, showed in vitro cytotoxicities against tumor cells that were more potent and more stable than authentic HA14-1, with IC 50 values in the nM range. In contrast, cytotoxic effects of these mHAs on normal cells were slight. Computational docking, colchicine-tubulin competitive binding, and tubulin polymerization studies demonstrated that these compounds bind at the colchicine binding site on tubulin and inhibit the formation of microtubules. Treatment of HL-60/Bcl-2 leukemia and CRL5908 lung cancer cells with these mHAs led to pronounced microtubule density decreases, G2/M cell cycle arrest, and apoptosis, as determined by immunofluorescence microscopy, flow cytometry, and DNA fragmentation analysis. These results support the continued development of these compounds as potential anticancer agents.
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HL-60/Bcl-2 cells (1x10 6 ) were treated with 1, 3, and 5 μM of mHA1, mHA6, mHA11, respectively, for 24 h at 37 °C. Cells were harvested at 1100 rpm and washed twice with PBS, then resuspended in 100 μl of PBS and 1ml of 75% cold ethanol and stored at -20 °C overnight. After centrifugation at 1100 rpm for 5 min, the supernatant was removed. A 500 μl PI staining buffer containing 80 μg/mL of propidium iodide, 100 μg/mL of RNAse A, and 1% Triton was added to the samples. The cells were incubated for at least half an hour and then analyzed by flow cytometry with a FACScalibur system (LSRII, Becton Dickinson) using FlowJo7.5 analysis software.
DNA fragmentation analysis
HL-60/Bcl-2 cells were resuspended in fresh medium and added to 24-well plate wells at a density of 1x10 6 cells/well, in a final volume of 1 mL. Vehicle control (DMSO), positive control (colchicine at 0.1 and 1 μM), and mHA1, mHA6, or mHA11 (at 1 and 5 μM)
compounds were then added to the appropriate wells. The plate was incubated for 24 h, and total DNA was extracted from the cells in each well using an Apoptotic DNA-ladder kit following the manufacturer's instructions (Qiagen). The DNA samples were subjected to 2%
agarose gel electrophoresis and visualized with ethidium bromide staining.
Tubulin polymerization assay
Tubulin polymerization assays were conducted using the polymerization assay kit following the manufacturer's instructions (Cytoskeleton, Inc.). Briefly, 50 μl of 3 mg/ml tubulin (>99% pure) proteins in G-PEM buffer (80 mM PIPES, pH 6.9, 2 mM MgCl 2 , 0.5 mM EGTA, 1 mM GTP, and 15% glycerol) was placed in 96-well microtiter plates in the presence of test agents. Polymerization was measured at every 60 sec intervals for 1 h using a Synergy 2 microplate reader (BioTek) (excitation at 360 nm and emission at 420 nm) at 37 °C. Tubulin levels were normalized to a value of 100 for the vehicle control. 
Immunolfluorescence staining
After treatment with 1 μM of mHA1, mHA6, and mHA11 for 24 h, the densities of microtubule and actin in adherent CRL5908 lung cancer cells were evaluated using immunobiochemistry. CRL 5908 cells at 5x10 4 per well were cultured as described previously. One day after seeding, 1 μM mHA1, mHA6, or mHA11 were added to the cells and cultured at 37 °C for 24 h. Thereafter, cells were fixed for 30 min at 4 °C in 4% paraformaldehyde and incubated with 0.1% Triton X-100 permeabilizing buffer for 15 min at Subsequently, all cells were stained with 1 μg/ml 4',6-diamidino-2-phenyl-indole (Sigma). Samples were examined under a fluorescence microscope (Eclipse TE2000-U, Nikon, Japan) and photographed using a digital camera equipped with a fluorescein figure analysis system (NIS-Elements F3.0; Nikon, Tokyo, Japan).
Molecular modeling
The crystal structure of alpha-beta-tubulin heterodimers in a complex with DAMAcolchicine [PDB reference: 1SA0 (16)] was used to predict the binding models of tubulin bind with designed compounds. The binding modes of designed ligands 1, 6, 11 with tubulin were predicted by using the Autodock4 program. In preparation of receptor grid files, a 60x55x60 grid with a grid spacing of 0.375 Ǻ was defined to cover the interface of α β-tubulin heterodimer. Grid maps were then generated by Autogrid4 for docking simulations. 
DNA fragmentation analysis
To confirm that these compounds could induce apoptosis in HL-60/Bcl-2 cells, we performed DNA fragmentation analysis which is a key feature of apoptosis (17). A clear DNA ladder was observed after 24 h treatment with 1 or 5 μM mHA1, mHA6, or mHA11 and 0.1 or 1 μM of colchicine, indicating that colchicine, and mHA1, mHA6, and mHA11 could induce apoptotic cell death in HL-60/Bcl-2 cells ( Figure 3B ). To determine whether the inhibition of growth due to HA14-1 analogs is associated with cell cycle perturbation, the distribution of cells in different phases of the cell cycle was determined by flow cytometry, and analyzed using FlowJo7.5 analysis software. The HL-60/Bcl-2 control cell population profile is shown in Table 1 and indicates that most of the cells were in the G1 and S phase. The HA14-1 analogs all caused a statistically significant increase in the G2-M cell population. For example, increased from 14.5% to 70.9%, 55.8%, and 54.7% were observed for mHA1, mHA6, and mHA11 treatments, respectively, when administered at 1 μM for 24 h. A concomitant decrease in G1 and S cell population was observed. The distribution of cells in different phases of the cell cycle is summarized in Table   1 . After exposure HL-60/Bcl-2 leukemia cells to 1, 3, and 5 μM of mHA1, mHA6, and mHA11, a sub-diploid peak was observed (Table 1 ). An increase in the sub-G0/G1 cell population from 5% to 13.3%, 13.9% to 20.3%, and 16.7% to 28.3% was occurred when cells were treated with 1 to 5 μM mHA1, mHA6, and mHA11, respectively, for 24 h.
G2/M cell cycle arrest caused by mHAs

All mHAs bind to colchicine-binding site and inhibit tubulin polymerization
In the crystal structure of of alpha-beta-tubulin heterodimers complex with DAMAcolchicine, colchicine binds at the interface of α/β-tubulin heterodimer and inhibits the assembly of tubulin by preventing curved tubulin from adopting a straight structure. The result of our docking study shows that mHA1, mHA6, and mHA11 could bind at the same To further determine whether the quantity and distribution of microtubule changes after treatment with these compounds, we performed an immunofluorescent staining study. Under normal culture condition, CRL 5908 cells were grown in spindle morphology and microtubules were arrayed along the long axes in the cytoplasm ( Figure 6 ). However, 24 h after treatment with mHA11 (similar results were obtained after treatment with mHA1 or mHA6), the 5908 cells had shrunk, and the cell shape was changed from spindle to round, irregular, or multi-angular. The long microtubule structure in cytoplasm was disrupted and the microtubule fluorescence intensity was significantly reduced, suggesting the decrease in contents of microtubule.
Docking study of HA14-1 analogs
The crystal structure of alpha-beta-tubulin heterodimers in a complex with DAMAcolchicine reveals that colchicine binds at the interface of the α/β-tubulin heterodimer and inhibits the assembly of microtubules by preventing curved tubulin from adopting a straight structure. The results of our docking study show that mHA1, mHA6, and mHA11 could bind 
at the same site as colchicine on the tubulin protein. mHA1 and mHA6 adopt a similar binding mode, which is slightly different from that adopted by mHA11 (Figure 7 ).
Discussion
HA14-1, the first reported Bcl-2 inhibitor identified by our group, can potently induce apoptosis in a wide variety of human cancers (12, 18-21). At concentrations above 10 μM, it also inhibits tubulin polymerization. We developed a series of HA14-1 analogs and identified a new class of 2-amino-4-phenyl-4H-chromene-3-carboxylate analogs: mHA1, mHA6 and mHA11 ( Figure 1 ). These analogs showed a more stable and more potent anticancer growth activity than did authentic HA14-1, with IC 50 values of less than 1 μM at 72 h in the HL-60/Bcl-2 cell line; while the IC 50 value for HA14-1 of was about 10 μM. These new analogs also exhibited a mode of action that is different from that of HA14-1. HA14-1 is a fastworking agent: it induces reactive oxygen species (ROS) generation, cytochrome c release, and caspase-9/-3 activation (18, 22) within few hours after administration of treatment, which suggested that these responses are its main mechanism for killing tumor cells. Typical morphological changes associated with apoptotic cells, such as cell shrinkage, nuclear fragmentation, and chromatin condensation, occurred within 6 to 24 h after treatment with HA14-1. However, these new analogs induced different types of morphological changes, including cell elongation, asymmetry and formation of long pseudopodia ( Figure 3A) . All of these changes suggested that these new analogs may target microtubule functions, which is important for maintenance of cell shape and for cell division. Our docking and protein-based binding studies provided further confirmed that these compounds bind at the same site as colchicine on the tubulin protein, causing disruption of tubulin polymerization (Figures 4-7) . Analysis of DNA content by flow cytometry indicated that cells were blocked in the G2/M phase and this was accompanied with a decrease in mitotic cells and an increase in apoptotic cells ( Table 1 overexpression of drug efflux pumps (24), mutations in the genes encoding α-and β-subunits of tubulin and differential expression of tubulin isotypes that reduce the binding of a drug to tubulin also contribute to MIA resistance (25, 26). Therefore, discovery of new MIAs like our HA14-1 analogs may be helpful in overcoming these problems and might offer advantages over the current agents used for chemotherapy. In contrast to our mHA agents, which inhibit tubulin polymerization, paclitaxel enhances tubulin polymerization and does not compete with colchicine binding to tubulin (Figures 4-6 ). These data provide evidence that our mHA agents exerted their anti-microtubule effects via different mechanisms, including differences in the sites of tubulin binding ( Figure 7 ). In addition, use of these MIAs in combination with other existing therapeutics could reduce the required doses of individual drugs, thereby lessening their toxicities and providing another way to overcome the shortcomings of currently used therapeutics (3, 27-29).
Bcl-2 is a proto-oncogene that prevents cells from undergoing apoptosis in response to cytotoxic stimuli. HL-60/Bcl-2 cells have been stably transfected with the pZip-Bcl-2 plasmid and they express higher levels of Bcl-2 protein than HL-60/neo cells do. Many rediscovered drug development strategies aim to affect multiple targets in a parallel fashion because multi-target drugs have a lower prevalence and reduced ranges of side effects than high-affinity, single-target drugs. mHA compounds were derived from HA-14-1, a known Bcl-2 binder and inhibitor. At concentrations lower than 5 μM, mHA compounds predominantly targeted microtubules. However, at concentrations around 5 μM, these mHA agents were also able to bind to Bcl-2 and inhibit Bcl-2 from binding with apoptotic protein- 
derived probes (our unpublished data). The dual-target effects of these mHAs on both microtubule and Bcl-2, and their biological significance (such as whether this contributes to their lower cytotoxic effects on normal cells, Figure 2 ), need to be investigated further.
In summary, we have developed a novel class of anti-microtubule agents that show promising antitumor activity. These new HA14-1 analogs inhibit tubulin polymerization, thereby inducing cell cycle G2/M arrest and apoptosis. The promising cytotoxic effects on cancer cells with IC 50 value at nM ranges, coupled with the minor cytotoxic effects on normal bone marrow cells, indicate that these new analogs have a good therapeutic window and that their further development as therapeutics for human use will be worthwhile.
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